Franklin Parlapiano Turner & Welch LLC Buys 3,737 Shares of Becton, Dickinson and Company $BDX

Key Points

• Franklin Parlapiano Turner & Welch LLC increased its holdings in Becton, Dickinson and Company by 11.5% in Q2, now owning 36,160 shares valued at approximately $6.2 million.
• Institutional ownership of Becton, Dickinson and Company stands at 86.97%, reflecting the confidence large investors have in the company.
• Currently, analysts have a consensus rating of "Hold" on the stock, with a price target averaging $205.40.

Franklin Parlapiano Turner & Welch LLC grew its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 11.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 36,160 shares of the medical instruments supplier's stock after acquiring an additional 3,737 shares during the period. Becton, Dickinson and Company accounts for about 1.6% of Franklin Parlapiano Turner & Welch LLC's investment portfolio, making the stock its 24th biggest position. Franklin Parlapiano Turner & Welch LLC's holdings in Becton, Dickinson and Company were worth $6,229,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Vanguard Personalized Indexing Management LLC boosted its holdings in Becton, Dickinson and Company by 20.4% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 21,493 shares of the medical instruments supplier's stock worth $3,704,000 after purchasing an additional 3,637 shares during the last quarter. Concurrent Investment Advisors LLC grew its holdings in shares of Becton, Dickinson and Company by 20.3% during the 2nd quarter. Concurrent Investment Advisors LLC now owns 13,742 shares of the medical instruments supplier's stock valued at $2,367,000 after purchasing an additional 2,319 shares during the last quarter. Stonehage Fleming Financial Services Holdings Ltd acquired a new position in shares of Becton, Dickinson and Company in the 2nd quarter worth approximately $61,000. Louisbourg Investments Inc. lifted its position in shares of Becton, Dickinson and Company by 35.8% during the 2nd quarter. Louisbourg Investments Inc. now owns 49,590 shares of the medical instruments supplier's stock valued at $8,542,000 after acquiring an additional 13,080 shares during the period. Finally, Aberdeen Group plc raised its holdings in Becton, Dickinson and Company by 33.2% during the second quarter. Aberdeen Group plc now owns 518,198 shares of the medical instruments supplier's stock worth $89,260,000 after buying an additional 129,209 shares during the last quarter. Institutional investors own 86.97% of the company's stock.

Becton, Dickinson and Company Stock Performance

Becton, Dickinson and Company stock opened at $186.41 on Friday. Becton, Dickinson and Company has a fifty-two week low of $163.33 and a fifty-two week high of $251.99. The stock has a fifty day moving average of $190.07 and a two-hundred day moving average of $186.03. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10. The company has a market capitalization of $53.43 billion, a price-to-earnings ratio of 33.53, a PEG ratio of 1.46 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. The company had revenue of $5.32 billion for the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%. On average, analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th were issued a dividend of $1.04 per share. The ex-dividend date of this dividend was Monday, September 8th. This represents a $4.16 annualized dividend and a dividend yield of 2.2%. Becton, Dickinson and Company's dividend payout ratio (DPR) is presently 74.82%.

Insider Activity at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,185 shares of the stock in a transaction that occurred on Friday, July 18th. The shares were sold at an average price of $180.29, for a total transaction of $213,643.65. Following the sale, the executive vice president owned 4,887 shares in the company, valued at approximately $881,077.23. This trade represents a 19.52% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Claire Fraser sold 917 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the transaction, the director directly owned 22,226 shares of the company's stock, valued at $4,167,375. This represents a 3.96% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 3,023 shares of company stock worth $562,036 over the last three months. 0.36% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on BDX shares. Wall Street Zen raised shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Piper Sandler reiterated a "neutral" rating and issued a $200.00 price objective (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Morgan Stanley boosted their price objective on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an "overweight" rating in a research note on Monday, August 11th. Royal Bank Of Canada began coverage on Becton, Dickinson and Company in a report on Thursday, September 25th. They set a "sector perform" rating and a $211.00 price target on the stock. Finally, Wells Fargo & Company upped their price objective on Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an "equal weight" rating in a research note on Friday, August 8th. Three analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $205.40.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.